These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36974661)
1. Current Advances and Future Prospects in Cancer Immunotherapeutics. Dede Z; Tumer K; Kan T; Yucel B Medeni Med J; 2023 Mar; 38(1):88-94. PubMed ID: 36974661 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. Highlights into historical and current immune interventions for cancer. Cole K; Al-Kadhimi Z; Talmadge JE Int Immunopharmacol; 2023 Apr; 117():109882. PubMed ID: 36848790 [TBL] [Abstract][Full Text] [Related]
4. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
5. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571 [TBL] [Abstract][Full Text] [Related]
6. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Luo C; Wang P; He S; Zhu J; Shi Y; Wang J Front Oncol; 2022; 12():919072. PubMed ID: 35795050 [TBL] [Abstract][Full Text] [Related]
7. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026 [TBL] [Abstract][Full Text] [Related]
8. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Shahvali S; Rahiman N; Jaafari MR; Arabi L Drug Deliv Transl Res; 2023 Jul; 13(7):2041-2056. PubMed ID: 36840906 [TBL] [Abstract][Full Text] [Related]
9. The next wave of cellular immunotherapies in pancreatic cancer. Yeo D; Giardina C; Saxena P; Rasko JEJ Mol Ther Oncolytics; 2022 Mar; 24():561-576. PubMed ID: 35229033 [TBL] [Abstract][Full Text] [Related]
10. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer. Sivaganesh V; Promi N; Maher S; Peethambaran B Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942 [TBL] [Abstract][Full Text] [Related]
11. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453 [TBL] [Abstract][Full Text] [Related]
12. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
13. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead. Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972 [TBL] [Abstract][Full Text] [Related]
14. Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells. Yazdanifar M; Zhou R; Mukherjee P Curr Trends Immunol; 2016; 17():95-115. PubMed ID: 28659689 [TBL] [Abstract][Full Text] [Related]
15. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Pennock GK; Chow LQ Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281 [TBL] [Abstract][Full Text] [Related]
16. Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Zimmermannova O; Caiado I; Ferreira AG; Pereira CF Front Immunol; 2021; 12():714822. PubMed ID: 34367185 [TBL] [Abstract][Full Text] [Related]
17. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy]. Hiramatsu H Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496 [TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245 [TBL] [Abstract][Full Text] [Related]
19. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685 [TBL] [Abstract][Full Text] [Related]